A Radiomic-Based Machine Learning Model Predicts Endometrial Cancer Recurrence Using Preoperative CT Radiomic Features: A Pilot Study.
artificial intelligence
endometrial cancer
personalized medicine
pre-surgical risk
prognosis
radiomic
recurrence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Sep 2023
13 Sep 2023
Historique:
received:
24
07
2023
revised:
23
08
2023
accepted:
11
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Current prognostic models lack the use of pre-operative CT images to predict recurrence in endometrial cancer (EC) patients. Our study aimed to investigate the potential of radiomic features extracted from pre-surgical CT scans to accurately predict disease-free survival (DFS) among EC patients. Contrast-Enhanced CT (CE-CT) scans from 81 EC cases were used to extract the radiomic features from semi-automatically contoured volumes of interest. We employed a 10-fold cross-validation approach with a 6:4 training to test set and utilized data augmentation and balancing techniques. Univariate analysis was applied for feature reduction leading to the development of three distinct machine learning (ML) models for the prediction of DFS: LASSO-Cox, CoxBoost and Random Forest (RFsrc). In the training set, the ML models demonstrated AUCs ranging from 0.92 to 0.93, sensitivities from 0.96 to 1.00 and specificities from 0.77 to 0.89. In the test set, AUCs ranged from 0.86 to 0.90, sensitivities from 0.89 to 1.00 and specificities from 0.73 to 0.90. Patients classified as having a high recurrence risk prediction by ML models exhibited significantly worse DSF ( Our findings demonstrate the potential of radiomics in predicting EC recurrence. While further validation studies are needed, our results underscore the promising role of radiomics in forecasting EC outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Current prognostic models lack the use of pre-operative CT images to predict recurrence in endometrial cancer (EC) patients. Our study aimed to investigate the potential of radiomic features extracted from pre-surgical CT scans to accurately predict disease-free survival (DFS) among EC patients.
METHODS
METHODS
Contrast-Enhanced CT (CE-CT) scans from 81 EC cases were used to extract the radiomic features from semi-automatically contoured volumes of interest. We employed a 10-fold cross-validation approach with a 6:4 training to test set and utilized data augmentation and balancing techniques. Univariate analysis was applied for feature reduction leading to the development of three distinct machine learning (ML) models for the prediction of DFS: LASSO-Cox, CoxBoost and Random Forest (RFsrc).
RESULTS
RESULTS
In the training set, the ML models demonstrated AUCs ranging from 0.92 to 0.93, sensitivities from 0.96 to 1.00 and specificities from 0.77 to 0.89. In the test set, AUCs ranged from 0.86 to 0.90, sensitivities from 0.89 to 1.00 and specificities from 0.73 to 0.90. Patients classified as having a high recurrence risk prediction by ML models exhibited significantly worse DSF (
CONCLUSIONS
CONCLUSIONS
Our findings demonstrate the potential of radiomics in predicting EC recurrence. While further validation studies are needed, our results underscore the promising role of radiomics in forecasting EC outcomes.
Identifiants
pubmed: 37760503
pii: cancers15184534
doi: 10.3390/cancers15184534
pmc: PMC10526953
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Cassa di Risparmio in Bologna
ID : J45F21002000001
Références
Front Oncol. 2023 Mar 02;13:1089807
pubmed: 36937399
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Sci Rep. 2020 Oct 20;10(1):17769
pubmed: 33082371
J Magn Reson Imaging. 2021 Mar;53(3):928-937
pubmed: 33200420
Nucl Med Mol Imaging. 2018 Apr;52(2):99-108
pubmed: 29662558
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
J Magn Reson Imaging. 2023 Jun;57(6):1922-1933
pubmed: 36484309
Int J Mol Sci. 2020 Sep 29;21(19):
pubmed: 33003368
Cancers (Basel). 2021 Feb 25;13(5):
pubmed: 33668727
Stat Med. 1997 Feb 28;16(4):385-95
pubmed: 9044528
Eur J Cancer. 2015 Sep;51(13):1742-50
pubmed: 26049688
Acad Radiol. 2004 Feb;11(2):178-89
pubmed: 14974593
Psychother Res. 2023 Jul;33(6):683-695
pubmed: 36669124
Front Med (Lausanne). 2022 Feb 24;9:833283
pubmed: 35280863
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2139-2146
pubmed: 30069578
Phys Imaging Radiat Oncol. 2019 Dec 17;13:1-6
pubmed: 33458300
Mol Imaging Biol. 2021 Oct;23(5):756-765
pubmed: 33763816
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Radiat Oncol. 2022 Dec 27;17(1):212
pubmed: 36575480
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:109-117
pubmed: 30306593
Acad Radiol. 2023 Sep;30 Suppl 1:S220-S229
pubmed: 36610930
Future Oncol. 2022 May;18(15):1873-1884
pubmed: 35293227
J Gynecol Oncol. 2014 Apr;25(2):136-47
pubmed: 24761218
J Comput Assist Tomogr. 2019 Jan/Feb;43(1):136-142
pubmed: 30371608
Eur J Surg Oncol. 2021 Nov;47(11):2734-2741
pubmed: 34183201
BMC Cancer. 2021 Nov 24;21(1):1266
pubmed: 34819042
Turk J Med Sci. 2022 Jun;52(3):762-769
pubmed: 36326312
Gynecol Oncol Res Pract. 2016 Dec 13;3:14
pubmed: 27999680
EJNMMI Res. 2018 Aug 22;8(1):86
pubmed: 30136163
Biometrics. 1983 Jun;39(2):499-503
pubmed: 6354290
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Radiographics. 2011 May-Jun;31(3):647-61
pubmed: 21571649
Obstet Gynecol. 2023 Jan 1;141(1):59-68
pubmed: 36701610
J Pathol. 2020 Mar;250(3):336-345
pubmed: 31829441
Front Oncol. 2022 Mar 02;12:864940
pubmed: 35311122
Am J Surg Pathol. 2013 Nov;37(11):1728-36
pubmed: 24061515
Int J Gynecol Cancer. 2010 Oct;20(7):1166-9
pubmed: 21495220
Comput Methods Programs Biomed. 2022 Jun;221:106906
pubmed: 35671602
Eur Radiol. 2019 Feb;29(2):792-805
pubmed: 29995239
PLoS One. 2016 Jun 21;11(6):e0157820
pubmed: 27326456
Eur Radiol. 2020 Aug;30(8):4306-4316
pubmed: 32253542
Diagnostics (Basel). 2021 Dec 24;12(1):
pubmed: 35054199
PLoS One. 2022 Jun 8;17(6):e0267727
pubmed: 35675289
Int J Cancer. 2019 Oct 1;145(7):1719-1730
pubmed: 30387875
Acta Radiol. 2021 Sep;62(9):1257-1262
pubmed: 32927957
Front Oncol. 2022 Aug 18;12:966529
pubmed: 36059674
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Indian J Surg Oncol. 2019 Mar;10(1):225-231
pubmed: 30948905
Cancers (Basel). 2021 Mar 23;13(6):
pubmed: 33806979
Front Oncol. 2019 Oct 09;9:1007
pubmed: 31649877
Eur J Radiol. 2022 Jan;146:110072
pubmed: 34861530
Int J Gynecol Cancer. 2020 Mar;30(3):378-382
pubmed: 32079712
J Pathol. 2020 Mar;250(3):323-335
pubmed: 31829442
Eur J Gynaecol Oncol. 2012;33(4):376-81
pubmed: 23091894
Diagn Interv Imaging. 2020 Jun;101(6):401-411
pubmed: 32037289
Eur Radiol. 2021 Jan;31(1):411-422
pubmed: 32749583
Cancer Imaging. 2020 May 1;20(1):33
pubmed: 32357923
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Br J Radiol. 2010 Jan;83(985):44-51
pubmed: 19620177
Int J Gynaecol Obstet. 2000 Aug;70(2):209-62
pubmed: 11041682
Korean J Radiol. 2019 Mar;20(3):405-410
pubmed: 30799571
AJR Am J Roentgenol. 2001 Mar;176(3):603-6
pubmed: 11222188
Eur J Radiol. 1998 Oct;28(3):250-5
pubmed: 9881261